4556 — Kainos Laboratories Balance Sheet
0.000.00%
Last trade - 00:00HealthcareAdventurousMicro CapContrarian
- ¥4bn
- ¥2bn
- ¥5bn
- 88
- 86
- 24
- 78
Annual balance sheet for Kainos Laboratories, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 953 | 1,964 | 2,244 | 2,677 | 3,020 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,215 | 1,201 | 1,206 | 1,333 | 1,411 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,830 | 3,806 | 4,058 | 4,690 | 5,219 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,572 | 2,539 | 2,532 | 2,535 | 2,547 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 5,859 | 6,745 | 6,962 | 7,572 | 8,116 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,660 | 1,848 | 1,894 | 1,781 | 1,916 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2,223 | 2,363 | 2,303 | 2,371 | 2,446 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 3,635 | 4,381 | 4,660 | 5,200 | 5,670 |
| Total Liabilities & Shareholders' Equity | 5,859 | 6,745 | 6,962 | 7,572 | 8,116 |
| Total Common Shares Outstanding |